The global Epigenetics market is estimated to be valued at US$ 1.7 billion in 2023 and is expected to exhibit a CAGR of 18.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
The Epigenetics market involves the study of heritable changes in gene function that do not involve changes to the underlying DNA sequence. Epigenetic modifications play a crucial role in various biological processes and have significant implications in the development of diseases, such as cancer and neurological disorders. The market offers a range of products and solutions, including epigenetic kits, reagents, enzymes, and instruments, that enable researchers to study and manipulate epigenetic modifications. The rising demand for epigenetic therapies and diagnostics, coupled with increasing funding for epigenetics research, is fueling the growth of the market.
Market Key Trends:
One key trend shaping the Epigenetics market is the increasing adoption of epigenetic therapies for cancer treatment. Epigenetic alterations are known to contribute to the development and progression of various cancers. Epigenetic therapies, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, are being developed and tested as potential treatments for cancer. These therapies target specific epigenetic modifications to reprogram gene expression and inhibit cancer growth. The growing understanding of epigenetic mechanisms and advancements in targeted therapies are expected to drive the adoption of epigenetic therapies in the coming years. Companies operating in the market are investing in research and development activities to develop novel epigenetic therapies with improved efficacy and reduced side effects.
Porter’s Analysis
The Epigenetics market is expected to witness high growth, exhibiting a CAGR of 18.1% over the forecast period of 2023-2030. This growth can be attributed to increasing research and development activities in the field of epigenetics, as well as the rising prevalence of chronic diseases such as cancer and cardiovascular diseases.
Threat of new entrants: The threat of new entrants in the Epigenetics market is relatively low. This is mainly due to the high barriers to entry, such as the need for significant investment in research and development, as well as the requirement for specialized expertise in the field of epigenetics.
Bargaining power of buyers: The bargaining power of buyers in the Epigenetics market is moderate. While buyers have some power to negotiate prices and terms with suppliers, the limited number of suppliers in the market gives them less leverage.
Bargaining power of suppliers: The bargaining power of suppliers in the Epigenetics market is moderate to high. This is because there are few major suppliers in the market, giving them more control over prices and terms. Additionally, suppliers in this market offer specialized products and services, further increasing their power.
Threat of new substitutes: The threat of new substitutes in the Epigenetics market is relatively low. The unique nature of epigenetic research and testing makes it difficult for alternative technologies or methods to replace epigenetic products and services.
Competitive rivalry: The competitive rivalry in the Epigenetics market is high. The market is dominated by a few key players, such as Illumina Inc., Thermo Fisher Scientific Inc., and Merck Millipore Limited. These companies compete fiercely to gain market share and develop innovative products and services.
Key Takeaways
The Global Epigenetics Market Demand is expected to witness high growth, exhibiting a CAGR of 18.1% over the forecast period of 2023-2030. This growth is driven by increasing research and development activities in the field of epigenetics, as well as the rising prevalence of chronic diseases.
In terms of regional analysis, North America is expected to be the fastest-growing and dominating region in the Epigenetics market. This can be attributed to the presence of key players, advanced healthcare infrastructure, and government initiatives to promote research and development in epigenetics.
The key players operating in the Epigenetics market include Illumina Inc., Thermo Fisher Scientific Inc., Merck Millipore Limited, Bio-Rad Laboratories, Inc., Qiagen Inc., Zymo Research Corporation, Diagenode s. a., Enzo Life Sciences, Inc., and New England Biolabs Inc. These players dominate the market due to their strong product portfolio, extensive distribution networks, and continuous investments in research and development.
In conclusion, the Epigenetics market is poised for significant growth over the forecast period. The market is driven by increasing research and development activities, as well as the rising prevalence of chronic diseases. North America is expected to be the fastest-growing region, while key players such as Illumina Inc. and Thermo Fisher Scientific Inc. continue to dominate the market.
Read more - https://www.newsstatix.com/epigenetics-market-analysis-share-value-dmand-and-forecast/
The growth in epigenetics market is primarily attributed to decreasing sequencing costs, increasing research activity, funding for epigenetics research, rising prevalence of cancer and growing applications of epigenetics in non-oncology diseases.
Expanding application areas of epigenetics in non-oncology diseases, personalized medicine, and target therapy are expected to provide growth opportunities for players operating in the market in the coming years.
Global Market for Epigenetics: Developed vs Developing Countries 2.
Declining Sequencing Costs and Time 5.
High Growth Potential in Emerging Markets 6.
Use of Epigenetics in Non-Oncology Applications The global epigenetics market is projected to reach USD 1.60 billion by 2022 from USD 0.85 billion in 2016, at a CAGR of 13.3%.
